Alzheimer 1-8

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease

P. B. Rosenberg, M. M. Mielke, D. Han, J. S. Leoutsakos, C. G. Lyketsos, P. V. Rabins, P. P. Zandi, J. C. S. Breitner, M. C. Norton, K. A. Welsh-Bohmer, et al.

Int J Geriatr Psychiatr.2012 Dec;27(12):1248-1257.

Abstract: Objective The use of psychotropic medications in Alzheimer’s disease (AD) has been associated with both deleterious and potentially beneficial outcomes. We examined the longitudinal association of psychotropic medication use with cognitive, functional, and neuropsychiatric symptom (NPS) trajectories among community-ascertained incident AD cases from the Cache County Dementia Progression Study. Methods A total of 230 participants were followed for a mean of 3.7?years. Persistency index (PI) was calculated for all antidepressants, selective serotonin reuptake inhibitors (SSRIs), antipsychotics (atypical and typical), and benzodiazepines as the proportion of observed time of medication exposure. Mixed-effects models were used to examine the association between PI for each medication class and Mini-Mental State Exam (MMSE), Clinical Dementia Rating Sum of Boxes (CDR-Sum), and Neuropsychiatric Inventory Total (NPI-Total) trajectories, controlling for appropriate demographic and clinical covariates. Results At baseline, psychotropic medication use was associated with greater severity of dementia and poorer medical status. Higher PI for all medication classes was associated with a more rapid decline in MMSE. For antidepressant, SSRI, benzodiazepine, and typical antipsychotic use, a higher PI was associated with a more rapid increase in CDR-Sum. For SSRIs, antipsychotics, and typical antipsychotics, a higher PI was associated with more rapid increase in NPI-Total. Conclusions Psychotropic medication use was associated with more rapid cognitive and functional decline in AD, and not with improved NPS. Clinicians may tend to prescribe psychotropic medications to AD patients at risk of poorer outcomes, but one cannot rule out the possibility of poorer outcomes being caused by psychotropic medications. Copyright (c) 2012 John Wiley & Sons, Ltd.

*Times cited: 3

Keywords: Alzheimer’s disease, antidepressants, antipsychotics, SSRI, cognition, psychosocial function, neuropsychiatric symptoms, epidemiology, pharmacoepidemiology, atypical antipsychotic medications, cache county, dementia, progression, depression, placebo, risk, ad, beneficiaries, metaanalysis

Link: http://www.ncbi.nlm.nih.gov/pubmed/22374884

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann